Expiration date: 05/2026
The composition and form of issue:
Tablets. 1 tablet contains:
bromocriptine mesylate 2,87 mg (corresponds to 2.5 mg of bromocriptine)
excipients: silica colloidal anhydrous magnesium stearate talc povidone corn starch microcrystalline lactose monohydrate
in vials to 30 PCs. in cardboard pack 1 bottle.
Description pharmaceutical form:
White or almost white, flat tablets, disk shape with cut edges, scored on one side and with the inscription "to 2.5" on the other.
Method of application and dose:
Inside, during a meal.
Menstrual disorders and female infertility: 1.25 mg 2-3 times a day, if necessary dose gradually increased to 5-7. 5 mg/day. Treatment should continue until normalization of the menstrual cycle and/or restoration of ovulation and for the prevention of relapses for several menstrual cycles.
Premenstrual syndrome: treatment begins on day 14 of the menstrual cycle from 1.25 mg/day, then gradually increase the dose by 1.25 mg/day to 5 mg/day (before the onset of menstruation).
Hyperprolactinemia in men: 1.25 mg 2-3 times a day, gradually increasing the dose to 5-10 mg/day.
Prolactinomas: 1.25 mg 2-3 times a day, gradually increasing the dosage to a few pills a day, to provide the desired level of prolactin in blood.
Acromegaly: initial dose 1.25 mg 2-3 times a day, then depending on clinical response and severity of side effects, you can increase the daily dose up to 10-20 mg.
To prevent lactation: 5 mg (2.5 mg 2 times a day) for 14 days. Treatment should begin a few hours after childbirth or abortion, but not in the first 4 h after them — after stabilization of vital body functions. 2-3 days after discontinuation of the drug there may be slight secretion of milk which elimination it is necessary to continue therapy with the same dose for another 1 week.
Beginning mastitis in the postpartum period: the dosage regimen is same as for the section "termination of lactation." If necessary, antibiotic therapy.
Postpartum breast engorgement: a 2.5 mg dose after 6-12 hours the dose can be repeated, unwanted stopping of lactation in this case does not occur.
Benign breast disease: 1.25 mg 2-3 times a day, the dose can be gradually increased to 5-7. 5 mg/day.
Parkinson's disease: to ensure optimal tolerability, treatment is initiated with a small dose is 1.25 mg 1 times a day, preferably in the evening, during 1 week. Dose gradually (weekly) increase by 1.25 mg, divided into 2-3 doses per day. The therapeutic effect occurs within 6-8 weeks of treatment, otherwise continue to increase the daily dose, weekly, increasing it by 2.5 mg/day. The average therapeutic dose for mono - and combined therapy is 10-40 mg/day. In the case of side effects, the daily dose is reduced after each new decrease the dose for at least 1 week. With the disappearance of adverse reactions, the dose can again be increased. Patients with motor impairments observed in patients receiving levodopa, it is recommended that prior to use of bromocriptine to reduce the dose of levodopa. If a satisfactory therapeutic effect can be further gradual reduction of the dose of levodopa, sometimes up to its complete cancellation. Bromocryptine treatment should begin simultaneously with the development of side effects of levodopa, such as dyskinesias, the effect of "end of dose", starting with the lowest effective dose. Higher doses are used in exceptional cases.
